Skip to main content

Table 2 The differences of treatment outcomes between CCRT and IMRT-SIB RT alone

From: Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma

Items LC P OS P DFS P DMFS P
  CCRT RT   CCRT RT   CCRT RT   CCRT RT  
Gender    0.13    0.30    0.1    0.30
 Male 77.9 89.9   70.2 77.8   62.9 72.3   79.9 81.4  
 Female 93.4 92.9   81.0 89.0   70.0 79.7   81.9 91.3  
Age    0.09    0.23    0.08    0.24
 ≤46 87.2 94.8   73.7 90.2   68.5 79.7   77.6 90.2  
 >46 72.7 86.3   69.2 71.3   57.7 68.3   81.2 80.9  
T3 89.2 92.4 0.93 69.3 84.0 0.45 63.2 68.4 0.31 77.4 81.9 0.82
T4 54.4 76.4 0.25 66.2 67.8 0.59 41.5 64.5 0.15 77.1 91.3 0.08
N0-1 73.4 84.0 0.85 72.2 76.7 0.35 51.5 82.9 0.09 67.3 96.9 0.02
N2-3 81.8 93.5 0.05 71.5 80.4 0.36 65.4 71.6 0.24 81.7 81.8 0.93
III 91.9 95.6 0.35 84.2 88.3 0.94 77.5 80.1 0.57 89.0 86.1 0.77
IV 63.8 63.6 0.352 54.3 71.5 0.24 43.6 61.3 0.15 64.8 86.3 0.12
IVA 47.1 78.6 0.11 62.2 69.2 0.43 34.3 74.7 0.01 68.1 95.5 0.03
IVB 84.0 64.0 0.55 50.0 73.9 0.41 55.6 45.0 0.62 62.5 73.1 0.86
Whole group 80.6 90.8 0.10 71.7 83.2 0.20 63.9 74.6 0.07 79.6 86.0 0.27
  1. LC: Local control; OS: Overall survival; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; RT: IMRT-SIB alone; CCRT: Concurrent chemoradiotherapy.